This brief review outlines current concepts concerning the aetiology and pathophysiology of pregnancy-induced hypertension and, based upon these concepts, presents a plan of intensive care management for the severe forms of this condition.
In discussing the management of pregnancy-induced hypertension (preeclampsia), Chesley stated in 1978 that 'Aside from the great variety of medications, surgical approaches have included ureteral catheterization, implantation of the ureters in the colon, renal decapsulation, drainage of spinal fluid, cisternal puncture, trepanation, ventral suspension of the uterus, post partum curettage, oopherectomies and so on. I do not rehearse the list in any spirit oflevity, for it is important to remember that each of the treatments was rational in the light of some hypothesis as to the cause or nature of eclampsia. That is more than we can say for our present management, which is purely empiric, perhaps too often symptomatic and in some respects based upon imitative magic'. I Although we still do not know the cause or causes of pregnancy-induced hypertension, we have recently begun to develop a better understanding of its pathophysiology.
Pregnancy-induced hypertension remains the commonest medical condition of pregnancy, affecting about 15% of primigravid pregnant women in Australia. 2 Its importance is underscored by the observation that it remains our commonest cause of maternal mortality3 and a substantial cause of neonatal morbidity and mortality.
Pregnancy-induced hypertension (PIH) is defined as the development of a diastolic blood pressure (BP) (phase IV) greater than 90 mmHg after twenty weeks gestation in a primigravida with no prior hypertension or renal disease. Moreover, the blood pressure returns to normal post partum. This diagnosis is most secure if these features are accompanied by an early ('booking') diastolic pressure less than 90 mmHg and a subsequent rise of more than 25 mmHg from this leve1. 4 It should be noted that neither oedema nor proteinuria are necessary for diagnosis but that proteinuria remains a hallmark of the severity of this disorder. 5 Finally, although this condition usually occurs in primigravidas, its occurrence in multigravidas is well documented, often but not always explained by a change ofpartners. 6 
CLINICAL SPECTRUM
It is important to realise that hypertension per se is but 'the tip of the iceberg' in PIH. It is present usually for only a few weeks, thus not having time to exert any of the more chronic end-organ effects seen in non-pregnant women with hypertension. However, it remains the single most important clinical sign as it alerts the clinician to the presence of PIH and serves as one marker of its severity. 7 The clinical spectrum of this condition varies widely. 8 On the one hand there may be a mild elevation in blood pressure late in the third trimester without maternal organ involvement and without influencing the pregnancy outcome; on the other hand the disorder may appear in the second trimester accompanied by heavy proteinuria followed by convulsions, disseminated intravascular coagulation, hepatic and renal failure and intrauterine death. In clinical practice it is useful to be aware that PIH may mimic disorders unrelated to pregnancy such as systemic lupus erythematosis, haemolyticuremic syndrome, acute hepatitis, idiopathic epilepsy and glomerulonephritis 9 and to 
Immunology
The observation by Brosens and co-workers l6 that placental bed blood vessels of women with severe PIH resembled blood vessels associated with a rejecting allograft fuelled the proposal that this disorder might have an immune basis. Various aspects of the immune system have since been studied in women with PIH leading to proposals that this is an immune complex disorder with resultant complement activation l7 and that there is failure of the normal maternal lymphocyte hyporesponsiveness to foetal cells in mixed lymphocyte culture. 18 As we do not yet understand the basis for the immunological 'tolerance' of normal pregnancy, confusion will remain about the role of the immune system in PIH for some time.
Perhaps the most attractive hypothesis to date is Faulk'sl9 proposal that there exist trophoblast antigens which are shared with maternal lymphocytes, so-called TLX (tropho blast-Iymphocyte cross-reacting) antigens. These TLX antigens may somehow modulate lymphocyte function, thereby protecting trophoblast from immune attack, or alternatively, trophoblast is protected during normal pregnancy by the presence of 'blocking antibody' which prevents recognition of these TLX antigens. It is proposed that a complete lack of these antibodies results in failure of implantation but if they are produced normally at the start and then become deficient as pregnancy progresses, PIH may result. Proof for this hypothesis is awaited. Although PIH is considered a disorder of primigravidas, it is well recognised that a change of male partners reverts the risk of developing PIH back to that of primigravid pregnancy. This has been shown in some cases to be associated with immunologic maternal/ paternal incompatability.20 Thus there are attractive hypotheses for an immunologic basis to this disorder but these mostly remain unproven or untested.
Placenta
Perhaps one of the most eXCItIng observations in women with PIH is the failure of normal 'placentation' which accompanies many such cases. 'Placentation' is the process whereby trophoblast invades the spiral arteries of the uteroplacental bed, converting them to low-resistance uteroplacental vessels capable of carrying up to ten times their previous blood flow, under low pressure. 21 This phenomenon occurs in the first trimester with a 'second wave' invasion in the early second trimester. It is now apparent that this process is lacking, or incomplete, in women with PIH,22 thus leaving vessels which are not only incapable of delivering the necessary blood supply to the foetus but still maintain a thick muscular coat which can vasoconstrict in response to circulating pressor agents such as angiotensin 11, adrenaline and arginine vasopressin, thereby further reducing placental blood flow. It is not clear why this process should fail, nor whether it is a primary or secondary event in these women, but it is apparent that abnormal placentation occurs prior to the clinical onset of PIH.
A further problem is that the placentas of many women with PIH contain intravascular coagulation 23 and/or the vasculopathy 'acute atherosis'24 which is the presence of fibrinoid necrosis and lipid-like infiltration of intrauterine vessels. It is only logical that all these changes in the uteroplacental vasculature result in placental ischaemia, an hypothesis central to the development ofPIH. This hypothesis remains difficult to prove in vivo of course, but continuous-wave doppler ultrasound velocimetry of both uterine and umbilical arteries shows an increased vascular resistance in women who have PIH. 25 • 26 Some state that this may even be predictive of the development of PIH or intrauterine growth retardation 27 though this prospect needs further evaluation. 28 
Prostaglandins
It has been proposed that one consequence of such placental ischaemia is a reduced production of vasodilator prostaglandins, in particular prostacyclin (PgI2). 29 Prostacyclin is an important mediator of both vasodilatation and inhibition of platelet aggregation. As PIH is characterised by both vasoconstriction and intravascular coagulation, studies of placental and systemic Pgl2 production in women with PIH have become most relevant.
Although various methodological problems have hampered studies of prostaglandins in pregnancy, the consensus view is that the production of placental Pg12, as measured by one of its stable metabolites 6-keto-PgFla, is decreased in women with PIH. At the same time, Walsh and Parisi 30 have shown that the production rate of placental thromboxane B2, the stable metabolite of TxA2, a potent vasoconstrictor and stimulus to platelet aggregation, is increased in these women. The net result, an increased ratio of thromboxane A2 to prostacyclin, tips the balance of these two opposing factors heavily towards vasoconstriction and platelet aggregation. It would seem likely that this occurs initially in the uteroplacental bed, thereby reducing placental blood flow further and enhancing this cycle of reduced placental prostacyclin production. However, Pgl2 can be produced by all vascular endothelium and this production is probably altered as well.
It has been proposed that in PIH, widespread vascular endothelial damage occurs either as part of an overall immune reaction or following intravascular coagulation, and this is supported by increased plasma levels of fibronectin and factor VIII related antigen in women with PIH,31 0 33 though more definite proof is awaited. Fitzgerald and co-workers,34 using gas chromatography/mass spectrometry, measured urinary 2,3 dinor 6-keto PgFla as a reflection of maternal systemic prostacyclin production. They found this to be reduced from early pregnancy in women who developed PIH in their third trimester, supporting the notion that systemic prostacyclin production is reduced in these women. Others, using radioimmunoassays, have not been able to confirm these findings. 35 ,36 
Coagulation and platelets
Conflicting data exist concerning the changes in the coagulation system of women with PIH. Studies of fibrin degradation products or the peptide fragments of thrombin, fibrinopeptide A and B, have been largely unrewarding. Several authors have, however, demonstrated a rise in the ratio of factor VIII related antigen (FVIII R:Ag) to factor VIII coagulation activity (FVIII:C) 33,37,38 and correlated this with severity of the disease. 38 This was originally interpreted to suggest activated coagulation but Scholtes and co-workers 33 showed that the major reason for this altered ratio was an increase in FVIII R:Ag, which is synthesised by endothelial cells and released upon platelet aggregation. They suggested that this most likely reflected endothelial damage with local platelet aggregation rather than a primary haematological disorder.
There is also agreement that plasma levels of antithrombin III (A TIll) are reduced in this condition,31,32,39 reflecting enhanced coagulation, often corresponding with placental infarction and poor foetal outcome 40 and associated with high levels of plasma fibronectin. 31 ,32 These studies indicate that the coagulation system is activated with subsequent consumption of A TIll, after initial endothelial damage with release of fibronectin and FVIII R:Ag into the circulation.
More recently attention has turned towards the role of the platelet in PIH. It has been proposed that the initial step in forming intravascular clots is platelet aggregation, occurring due to the lack of vascular prostacyclin and resulting in intravascular coagulation and decreased plasma levels of AT Ill, as above. This process has been reviewed in detail recently.41 However, more recent evidence suggests that some such patients may also have an immune-mediated thrombocytopenia due to platelet bound IgG antibody. 42 Whatever the exact mechanisms involved it IS apparent that intravascular coagulation, either local or disseminated, is a major feature of PIH, particularly in the more severe forms of the disorder.
Volume homeostasis
Normal pregnancy IS accompanied by weight gain, a large amount of which is extracellular fluid (ECFV) accumulation of salt and water. The ECFV, comprising predominantly the interstitial fluid (lSFV) and plasma volumes (PV), is ultimately dependent upon renal retention or loss of sodium. However, within this fluid volume transcompartmental fluid shifts occur dependent upon transcapillary Starling force~ and vascular permeability. These aspects of volume homeostasis in pregnancy have been reviewed recently. 43, 44 In pregnancy the maternal plasma volume has a pivotal role in foetal outcome. It is well recognised that the degree of PV expansion correlates positively with foetal birth weight 45 ~nd th~t pregnancies complicated by Intrautenne growth retardation alone, or by hypertension, are associated with a reduced maternal plasma volume. 46 ,47 While several studies have confirmed a reduced maternal plasma volume in women with PIH,47,49 the distribution of total extracellular fluid volume in these women is unc~ear. The appearance of rapid weight gain, perIpheral oedema, proteinuria and hypertension would signify that this woman with PIH has a reduced plasma volume but an increased.ISFV. On the other hand, many women with .PIH do not develop oedema, a subgroup which Chesley has found to have a worse foetal outcome. 50 The absence of oedema suggests that these women do not have an increased ECFV. If this is so, then therapies directed towards these groups would need to be very different but only one study has addressed this question in any way. Gallery et af.51 measured the PV and ISFV of four subgroups with PIH: those with proteinuria with and without oedema, and those without proteinuria, with and without oedema. All had reduced plasma volume from that of normotensive pregnant women but only those non-proteinuric women with oedema had an increased ISFV. However a re-analysis of their mean data show that' in normal pregnancy the ratio of PV to ISFV is approximately 0.47 whether there is oedema or not. On the other hand, this ratio is reduced in women with PIH, i.e. a greater proportion of total ECFV is in the ISF space, and further reduced if oedema is present independent of the presence or absence of proteinuria. These data therefore support the clinical observation that in women with PIH and oedema there is greater redistribution of fluid from the plasma volume to the ISFV than in those without oedema, independent of the presence of proteinuria.
The mechanisms for this redistribution of ECFV remain unknown but some, and often conflicting, evidence has been proposed for the concept that this results from reduced colloid osmotic pressure 52 -55 and/or increased capillary permeability due to vascular endothelial injury. [55] [56] [57] No attempts have been made to elucidate the cause of reduced PV in those without oedema where the redistribution of fluid among the ECFV appears less deranged. On first principles it is possible that some of these women have an inappropriate degree of sodium loss but this remains to be established. . Whatever the derangements of ECFV early In the development of this disorder, there is no doubt that sodium retention follows the clinical appearance of proteinuric PIH. To ~xamine this in more detail, we gave Intravenous saline infusions to women with PIH .and to normotensive primigravidas who had Ingested a wide range of sodium intakes prior to the study (Figure 2 ).58 Those with protein uric PIH had the lowest plasma volumes and retained sodium avidly, to the same degree as salt depleted normotensives, ~n appropriate physiological response to llltravascular volume depletion. Those without proteinuria, whose plasma volumes were not reduced significantly from normal, excreted sodium similarly to other ad libitum salt-eating normotensives. These data were not analysed in terms of the presence or absence of oedema but these questions are currently being addressed.
Renin-angiotensin-aldosterone (R-A-AJ system
There is little doubt that renin exists in both maternal kidney and the uteroplacental unit 59 but at present there is no way to differentiate these systems in vivo. All the components of this system are stimulated in normal pregnancy but still respond appropriately around their new baselines to dietary sodium modification,60 intravenous saline loading 59 ,61 and posture. 62 Furthermore there is refractoriness to the vascular (pressor)63 and antinatriuretic 61 effects of angiotensin 11 in normal pregnancy though adrenal sensitivity is retained. 61
In PIH, plasma renin and aldosterone concentrations are reduced 59 ,64 and refractoriness to the pressor effects of All is lost. 63 The explanations for all these observations remain unknown though it has been proposed that a deficiency of prostacyclin, which can stimulate renin release directly65 and causes vasodilatation, might result in these alterations. Although it was popularly proposed that reduced plasma renin followed sodium retention in PIH, the discovery that the plasma volume is reduced in the face of this sodium retention necessitated a review of this hypothesis and we have also challenged this concept. 58 It seems more likely that the R-A-A system lacks a stimulatory factor, and a deficiency of PgI2 would explain most of the derangements of the R-A-A system in women with PIH.
Summary
While the aetiology of PIH is not known, it seems there is a genetic predisposition which may allow for an immune response within the placenta, though the evidence for this is by no means conclusive. More is known of the ensuing pathophysiology and central to these changes is the concept of reduced uteroplacental perfusion and function consequent upon failure of normal 'placentation'. It is an attractive hypothesis, awaiting confirmation, that the next step of failing prostacyclin production leads to intravascular coagulation, endothelial damage and subsequent loss of plasma volume to the ISFV as well as loss of the usual vascular refractoriness to angiotensin 11. These events result in the appearance of oedema, hypertension due to increased peripheral resistance, and most importantly, reduced perfusion of kidneys, liver, brain and placenta, the latter completing the 'feedback loop' of this mechanism. It also seems likely that in terms of altered volume homeostasis this is a heterogeneous condition and that there exists an important subset of women who have reduced plasma volume and plasma renin concentration, without oedema, who may have subtle sodium loss as their primary alteration in ECFV. However, the end result for these women is the same as those with oedema, as they share a common final pathway of reduced organ perfusion.
MANAGEMENT OF SEVERE PIH

Recognition of the disorder
The disorder has been defined early in this review. It is important however to be alert to the women 'at risk' of developing PIH so as to intervene as early as possible in the hope of ensuring a successful pregnancy outcome. The condi tion is more common among primigravidas, those with a family history of PIH or eclampsia, in multiple pregnancy, in the teenage or elderly primipara, and in those with previous PIH. While the development of hypertension in a second or subsequent pregnancy should prompt a search for underlying essential or secondary forms of hypertension, this disorder can occur in multigravidas, particularly following a change of partners, or be recurrent. This latter group is thought to represent those at risk of essential hypertension in later life. 66 Apart from identifying the patient at risk, it is important that phase IV diastolic blood pressure be measured using an appropriately sized cuff with the patient sitting and the arm at the level of the heart. 67 Values measured with the patient in lateral recumbency will be approximately 10 mmHg lower. 68 These might seem trite observations but potentially lifesaving or life-threatening decisions may be made on the basis of these readings. Timing of delivery This is the single most important decision in the management of PIH. The maternal condition improves after delivery and it is therefore necessary to decide whether the foetus will benefit from a prolonged stay in utero. In some cases, e.g. the abrupt onset of severe PIH close to term, the decision to deliver is easy, but in cases where the foetus is premature, this decision is much more difficult. The decision is best made, as is all of the management of PIH, by discussion among obstetrician, neonatologist, physician or in tensi v ist, and anaesthetist. I n the meanwhile, some guidelines are required though these should not be considered exhaustive or dogmatic (Table 3) .
Assessment of severity
Antenatal management (a) Monitoring
Maternal and foetal monitoring are vital to detecting changes which may indicate that prolongation of pregnancy is no longer safe. At least daily clinical assessment is necessary, paying attention to blood pressure, urine output, urinalysis, reflexes, fundoscopy, presence or absence of oedema, cardiovascular examination, foetal heart sounds and uterine size. These observations are designed to assess the overall disorder and detect severe disease as described in Table 2 . Investigative monitoring includes measurement of serum uric acid (the level of which correlates with risk of foetal mortality),69 creatinine, bilirubin, aspartate transaminase (AST) and platelet count, to detect subclinical evidence of organ dysfunction (Table 2) . Foetal monitoring remains difficult. Cardiotocographic changes are often late and indicate the need for urgent delivery and most centres have abandoned the The level of BP at which antihypertensive therapy should be instituted remains a widely debated issue. It is our unit's practice, as is others,1°,71 to institute oral maintenance antihypertensive therapy if the diastolic blood pressure (DBP) remains above 90 mmHg despite overnight bed rest in hospital and to treat hypertension acutely if the DBP is greater than or equal to 110 mmHg, or greater than 105 mmHg with other associated features of severe disease. Many regimes are in use around the world for acute treatment of hypertension, including intravenous hydralazine, diazoxide, labetalol, clonidine or oral nifedipine. 72 . 75 Although both hydralazine and nifedipine appear equally effective, we use initially sublingual nifedipine 10 mg every twenty minutes to a maximum of 30 mg, as this is easy to administer and can be done while venous access is being established. Although the amount absorbed sublingually may be variable, this has been well tolerated and has lowered the blood pressure effectively and without any precipitous falls. Alternatively, intravenous boluses of hydralazine 5 mg have achieved the same results, though in our experience are more often accompanied by nausea and tremulousness than with nifedipine. If these combined measures are ineffective, a slow continuous infusion of hydralazine, approximately 5 mg per hour titrated against blood pressure responses, has proven safe and effective.
The major aim of acute therapy of hypertension is to prevent intracerebral haemorrhage while not interfering with uteroplacental blood flow by lowering the blood pressure too far. Both these aims can be achieved if the systolic BP is maintained around 140 mmHg and the diastolic 90-104 mmHg after such treatment and attention is paid to maintenance of intravascular volume at the same time (vide infra). If the pregnancy is to be prolonged, oral antihypertensives, either oxprenolol or methyldopa (the latter if there is any contraindication to beta-blocker therapy) are used in our unit to slowly lower the BP to 110-140 mmHg systolic and 80-90 mmHg diastolic. Other regimes exist and are equally effective. 70 ,71,76 We do not aim to achieve normal BP but rather to protect against acute haemorrhagic problems.
Based upon the pathophysiology discussed above, the use of ACE inhibitors or prostacyclin infusions might seem reasonable. Both have been tried, and although providing support for the concept that this condition is due to prostacyclin deficiency, are associated with a high rate of foetal loss in animal and human studies.77-78 It is not clear whether these deaths occurred due to the medications per se, their dosages or their physiologic effects, but at present these must remain contraindicated in clinical practice.
(c) Volume homeostasis (i) Monitoring
As this condition can be viewed as one of organ hypoperfusion, attention to intravascular volume, particularly when inducing vasodilatation with antihypertensive therapy, is imperative. Some argue this as a case for invasive monitoring with central venous pressure (CVP) or pulmonary capillary wedge (PCWP) pressures,79 but many of these patients with severe PIH will have thrombocytopenia and/or DIC prohibiting these manoeuvres. While it is not our unit's practice to routinely employ these measures, others do so and find it an advantage in their management of fluid therapy. 80 The final decision to use such invasive monitoring must be left to the individual but it is important to note that even in centres where haemodynamic monitoring is well established for both clinical and research purposes, only a modest correlation exists between CVP and PCWP in this condition and it is impossible to predict in which patients this correlation will occur. 81.82 As left ventricular filling pressure is the most relevant physiologic measurement required in these patients, either Swan-Ganz catheterisation should occur or the patient should not have invasive monitoring. Fluid therapy should not be determined on the basis of evp measurements alone in women with
PIH. (ii) Fluids
Intravascular volume expansion with SPPS 500 ml has been shown to reduce the blood pressure per se 5 1.
83 though the clinical indications for this are unclear. Based upon the principles discussed above, volume expansion would appear both beneficial and safe in those women with PIH and no oedema, who seem to have relatively less redistribution of plasma volume to the ISFV compared with those with oedema. We use 500 ml SPPS given over two hours to help stabilise the BP and maintain intravascular volume in women with severe PIH and no oedema who have a haematocrit of 0.40, which is greater than two standard deviations above the third trimester mean for our pregnant population. As the usual plasma volume deficit is of the order of 3-4 mllcm height, i.e. approximately 400-600 ml, this volume should be adequate initiallv and the haematocrit is determined again the following day. If significant oedema is present then we do not routinely use volume expanders as this group appears to have a greater redistribution of extracellular fluid and is more likely to have increased capillary permeability, as discussed above, thus making this the subset of patients theoretically most at risk of developing non-cardiogenic pulmonary oedema if volume overloaded. 84
The patient with oedema, oliguria and renal insufficiency presents a peculiar difficulty in that intravascular volume is likely to be reduced, must be corrected in order to prevent progression to established acute tubular necrosis, yet this therapy may result in pulmonary oedema for the reasons discussed above. Such patients should be managed in an intensive care setting and should be delivered as a first priority. Intravenous therapy, with colloid solutions, is necessary and is best guided by pewp measurements in this situation. It 85 One index often used to assist in the differential diagnosis of oliguria is the fractional excretion of sodium (FENa), the fraction of filtered sodium appearing in the final urine. An elevated fractional excretion of sodium suggests that acute tubular necrosis has developed while a low FEN a suggests prerenal hypoperfusion or the presence of glomerular 'endotheliosis'. While FENa and other urinary indices are often reliable aids in making these distinctions in non-pregnant subjects,86 their use in women with severe PIH and oliguria, when evaluated during haemodynamic studies, has not been as reliable. 87 Although various treatments such as plasma exchange and heparinisation have been tried for the management of ARF in PIH, maintenance of intravascular volume and vasodilatation remain the mainstay of therapy. Thereafter, renal recovery is likely to occur once the patient has been delivered though dialysis may be necessary in the interim. Prolonged oliguria or anuria may herald renal cortical necrosis, a condition more common in pregnant than in nonpregnant women, and renal functional recovery from this lesion is less likely.
(e) Convulsions
Eclampsia is now a rare disorder, largely due to delivery being effected when convulsions appear imminent, as detected by hyperreflexia, clonus and fundal vasospasm. However, this has been reported to occur up to ten days post partum following severe PIH 88 and the clinician should be alert to this possibility.
Intravenous diazepam remains the best therapy for treatment of convulsions but more emphasis is now placed upon prevention of fitting. In the United States magnesium sulphate is widely used for this purpose and has been quite successfuF though it should probably be used only in centres experienced with its use. Phenytoin has now become accepted as a form of convulsion prophylaxis for women with PIH and when used carefully gives adequate maternal blood levels and is clinically effective. 89 Loading doses to give therapeutic blood levels can be achieved safely using either oral or intravenous regimens. 89 Chlormethiazole has been equally useful for convulsion prophylaxis but its propensity to induce respiratory depression makes it more difficult to use and gradually phenytoin seems to have been adopted as first line therapy for this purpose outside the United States.
These two problems tend to occur together, are present in a small percentage of patients 90 and may form part of the so-called 'HELLP' (haemolysis, elevated liver enzymes, low platelets) syndrome. This term should probably be abolished to discourage these features being viewed as anything other than those of severe PIH. If progressive, these abnormalities are indications for delivery. Occasionally, abnormal liver function will respond to vasodilator therapy and/or intravascular volume expansion, but good information on this is lacking.
Thrombocytopenia, though possibly immune as discussed above, usually signifies the occurrence of intravascular coagulation. At this stage blood pressure control should be meticulous to prevent haemorrhage (cerebral or retroplacental) and platelet infusions may be necessary as short-term therapy. Combined therapy with a beta-adrenergic blocker and low-dose aspirin may prove to be useful in this situation 91 but is not yet standard therapy.
POST PARTUM MANAGEMENT
While it can be anticipated that all the maternal problems discussed above will be cured by delivery it should be noted that the condition often worsens for three to four days post partum. For this reason we control the blood pressure aggressively during this stage and continue to monitor renal and hepatic function and the platelet count. Therapy during the post partum period should be supportive, in the anticipation that full recovery will occur, though complications such as renal failure l}'iay lead to long-term dialysis requirements,as discussed above.
Most patients are able to be discharged from hospital within seven to ten days on no medications, having gained full recovery. It has recently been proposed that up to 90% of those with early-onset PIH have underlying renal disease, usually 19A nephropathy, or essential hyperteqsion 92 though this has not been our experience or the experience of others. 93 Nevertheless, it is prudent to search for underlying renal disease or hypertension in those who have presented early, and routine follow-up two to three months post partum is warranted.
PREVENTION
Examination of Figure 1 shows that a central problem in the development of PIH is the altered prostacyclin/thromboxane A2 ratio. For this reason low-dose aspirin has been introduced as both prevention and therapy for this disorder 91 ,94-96 with the aim of inhibiting platelet thromboxane A2 formation while allowing the production of vascular prostacyclin. Two early studies, when considered together, have shown a beneficial effect of low-dose aspirin from early pregnancy in preventing foetal loss, intrauterine growth retardation and the development of this disorder in women considered at risk of developing PIH. 94 ,95 Others have also reported encouraging results 96 and several large multicentre studies are now underway to determine the role of low-dose aspirin in the prevention and management of PIH.
CONCLUSIONS
Chesley's quote from ten years ago 1 that our management of this condition is purely empiric may now be revised. It is clear that the precise aetiology of PIH remains unknown but equally clear that research advances in the past decade have provided us with a working hypothesis for this condition (Figure 1 ). Based upon this hypothesis, a rational plan of management of PIH has been presented, though of course this may require major revisions in the years to come as more is learned about this condition. In the meanwhile a large amount of clinical and scientific research is required to shape future 
